Home » White House Withdraws Heidi Overton’s FDA Nomination After Bipartisan Pushback

White House Withdraws Heidi Overton’s FDA Nomination After Bipartisan Pushback

by Richard A Reagan

The White House has withdrawn President Donald Trump’s nomination of Heidi Overton to lead the Food and Drug Administration (FDA). The decision follows opposition from Democrats, some Republicans, and activists within the Make America Healthy Again (MAHA) movement.

The withdrawal came Tuesday, November 17, just one day before the Senate Health, Education, Labor, and Pensions Committee was scheduled to vote on her nomination.

A senior administration official told Axios that Overton did not have sufficient support in Congress to secure confirmation.

“FDA nominee Heidi Overton lacks the support on the Hill to move forward with her confirmation,” the official said.

The official added that the administration needed a new direction at the FDA and remained committed to Health Secretary Robert F. Kennedy Jr.’s MAHA agenda.

Trump nominated Overton in August to replace former FDA Commissioner Martin Makary, who resigned in May. Overton, a preventive medicine physician, serves as a deputy director of the White House Domestic Policy Council.

Her nomination drew criticism from lawmakers in both parties over her qualifications and positions on vaccines and other health policies.

Sen. Bill Cassidy (R-LA), chairman of the Senate health committee, previously expressed serious concerns about Overton’s lack of managerial experience.

He also questioned her involvement in the administration’s efforts to revise childhood vaccination recommendations, suggesting that her role raised doubts about her commitment to scientific evidence and children’s health.

However, Cassidy disputed the White House’s explanation for withdrawing her nomination.

In a statement Tuesday evening, Cassidy said he had been making progress in discussions with other senators and believed Overton could have secured confirmation.

“I believe she would have had the votes to pass out of committee and pass the full Senate,” he wrote.

Cassidy also said anti-abortion senators had sought additional assurances from the administration about its commitment to their priorities. According to Cassidy, the White House withdrew Overton’s nomination instead of providing those commitments.

Democrats had also opposed her nomination.

Sen. Patty Murray (D-WA) publicly urged senators to reject Overton, arguing that she should not be responsible for overseeing the safety of the nation’s food and medicines.

Meanwhile, several influential MAHA activists questioned Overton’s nomination, alleging that she was too closely aligned with pharmaceutical and agricultural interests.

Some activists believed she would undermine Kennedy’s efforts to reform federal health policies.

MAHA advocate Alex Voetberg credited grassroots opposition for the withdrawal, disputing suggestions that concerns among Senate Republicans were primarily responsible.

“The explanation they’re looking for is the power of MAHA activists,” she wrote.

Overton also faced questions from some anti-abortion advocates who doubted whether she would impose stricter regulations on mifepristone, a drug used in medication abortions.

However, other anti-abortion organizations supported her nomination. Americans United for Life endorsed Overton in August, citing her medical background and ability to evaluate the drug’s safety.

When Trump initially nominated Overton, he praised her work in his administration and said her leadership was necessary to maintain America’s position in medical research and scientific discoveries.

Her withdrawal leaves the FDA without a Senate-confirmed commissioner. Kyle Diamantas has served as acting commissioner since May 15.

The White House must now select another candidate to lead the agency, although it remains unclear when a replacement will be announced.

 

You may also like

WP Twitter Auto Publish Powered By : XYZScripts.com